You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 24, 2024

Investigational Drug Information for Giredestrant


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for Giredestrant?

Giredestrant is an investigational drug.

There have been 15 clinical trials for Giredestrant. The most recent clinical trial was a Phase 1 trial, which was initiated on June 1st 2022.

The most common disease conditions in clinical trials are Breast Neoplasms, Endometrial Neoplasms, and [disabled in preview]. The leading clinical trial sponsors are Hoffmann-La Roche, Genentech, Inc., and MedSIR.

There is one US patent protecting this investigational drug and thirty-one international patents.

Recent Clinical Trials for Giredestrant
TitleSponsorPhase
A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC PopulationMedSIRPhase 2
A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast CancerHoffmann-La RochePhase 2
A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast CancerETOP IBCSG Partners FoundationPhase 2

See all Giredestrant clinical trials

Clinical Trial Summary for Giredestrant

Top disease conditions for Giredestrant
Top clinical trial sponsors for Giredestrant

See all Giredestrant clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.